Apr 15 |
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
|
Apr 8 |
TFF Pharmaceuticals files to sell common stock, warrants
|
Mar 28 |
TFF Pharmaceuticals GAAP EPS of -$2.01, revenue of $0.1M
|
Mar 28 |
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
|
Mar 27 |
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
|
Mar 25 |
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation...
|
Mar 20 |
TFF Pharmaceuticals announces $1.2M registered direct offering
|
Mar 20 |
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
Mar 20 |
TFF Pharma gains after portfolio shakeup
|
Mar 20 |
TFF Pharmaceuticals Announces Update on Clinical Programs
|